Burjel launches Thalassemia & Sickle Cell Middle in Abu Dhabi
Burjel Holdings has inaugurated the Thalassemia & Sickle Cell Middle in Burjel Medical Metropolis in Abu Dhabi, from which the care is improved for individuals with hereditary blood problems.
The middle is about to supply a affected person -oriented method to therapy, supported by a multidisciplinary workforce of specialists. It really works seven days every week, with a particular transfusion unit and totally built-in outpatient companies.
It’s positioned with in depth transfusion companies within the VAE by way of the Burjel hospital community, globally validated MRI quantification of iron overload within the liver and the guts, and inside molecular genotyping choices.
Specialists from the Thalassemia & Sickle Cell Middle can handle each pediatric and grownup instances, with the excessive prevalence charges of those ailments within the area.
The middle, situated in a quaternary care establishment, ensures that varied medical and surgical subspecialties are instantly accessible.
This facilitates seamless references and the administration of issues related to thalassemia and sickle cell illness.
Burjeel Holdings Group Chief Analysis Officer and Thalassemia & Sickle Cell Middle Director Khaled Musallam mentioned: “What makes this heart distinctive is the mixture of world scientific experience, entry to the newest therapies and the potential for offering care in accordance with worldwide tips written by the individuals main the companies right here.”
The healthcare vary of the middle consists of analysis as much as and together with maturity, with personalized transition packages and coverings for varied thalassemia problems and sickle cell ailments.
It adheres to the worldwide norms and consists of these of the Thalassemia Worldwide Federation, with changes to the native inhabitants.
As well as, the middle will collaborate with the middle for analysis into uncommon blood problems in Burjel Medical Metropolis, led by Khaled Musallam, to register sufferers in international scientific research.
This partnership presents entry to the newest therapy improvements that embrace illness -modifying and healing therapies.
Final month Burjel Holdings collaborated with the corporate Paige, primarily based within the US, to implement AI authorized by the FDA within the diagnostics of most cancers within the Mena area.
